| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 94‐114 mm Hg on 2 consecutive visits (one week apart) of run‐in; 4‐week double‐blind treatment |
| Participants |
Cilazapril 1.25 mg: n=6(5 males,1 female); age=41(5) years; baseline sitting SBP=133(7) mm Hg, DBP=97(3) mm Hg, HR=77(5) bpm;
Cilazapril 2.5 mg: n=6(5 males,1 female); age=44(13) years; baseline sitting SBP=146(17) mm Hg, DBP=100(10) mm Hg, HR=77(13) bpm;
Cilazapril 5 mg: n=6(4 males,2 females); age=42(9) years; baseline sitting SBP=144(8) mm Hg, DBP=98(4) mm Hg, HR=72(8) bpm;
Placebo: n=6(3 males,3 females); age=48(8) years; baseline sitting SBP=150(10) mm Hg, DBP=101(3) mm Hg, HR=65(9) bpm |
| Interventions |
Cilazapril 1.25 mg once daily;
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo;
taken at 8 AM |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
Trough erect SBP/DBP using mercury sphygmomanometer;
Trough supine HR;
Trough erect HR;
WDAE |
| Notes |
Only cilazapril 2.5 mg and placebo groups have BP >/= 140/90 mm Hg after placebo run‐in; used supine BP for cilazapril 2.5 mg and placebo groups only; BP change reported and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; data from Table 4, p. 55; Jadad score=3; funding source= Hoffman‐La Roche |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
